Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours

Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belusa R

Authors: Knigge U, Kjellman M, Grønbæk H, Thiis-Evensen E, Schalin-Jäntti C,

Keywords: prediction, progression, machine learning, SI-NET, serum protein,

#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm

Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,

Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,

#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dam G, Grønbæk H, Sørbye H, Thiis-Evensen E, Paulsson B,

Keywords: gep-net, ct, cga, correlation,

#2109 Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ali A

Authors: Ali A, Grönberg M, Hjortland G, Grønbæk H, Ladekarl M,

Keywords: chemotherapy, Neuroendocrine Neoplasms, Intravenous, Oral, survival,

#2089 Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs

Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,

Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,